CapForce (OPGN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
26 Jan, 2026Executive summary
The annual meeting is scheduled for February 23, 2026, and will be held virtually, allowing shareholders to vote online or by proxy in advance.
Seven key proposals will be presented, including director elections, a new equity incentive plan, warrant exercise approval, share sale ratification, a company name change, a say-on-pay vote, and auditor ratification.
The Board recommends voting in favor of all proposals and has set January 5, 2026, as the record date for voting eligibility.
Voting matters and shareholder proposals
Proposals include electing five directors, approving the 2026 Equity Incentive Plan, authorizing issuance of up to 889,274 shares upon warrant exercise, ratifying the sale of 7,200,000 shares to AEI Capital Ltd., changing the company name to CapForce Inc., an advisory say-on-pay vote, and ratifying Beckles & Co., Inc. as auditor.
Each proposal has specific voting requirements, with most requiring a majority of votes cast, and the director election decided by plurality.
The Board is not aware of any other business to be presented at the meeting.
Board of directors and corporate governance
The Board consists of five members, with two classified as independent under Nasdaq rules.
The company operates as a controlled company and is exempt from certain Nasdaq independent director requirements.
Audit and Compensation Committees are in place, with written charters and annual elections; the full Board handles nominating and governance responsibilities.
The Board emphasizes diversity and regularly reviews its composition and leadership structure.
Latest events from CapForce
- All seven proposals, including director elections and a name change, were approved by majority vote.OPGN
AGM 202623 Feb 2026 - Shareholders will vote on seven key proposals, including a new equity plan and company name change.OPGN
Proxy Filing6 Feb 2026 - Q2 2025 revenue reached $4.0M from listing sponsorship, with net income of $3.5M.OPGN
Q2 202531 Oct 2025 - OpGen posted $8.9M Q3 net income, exited diagnostics, and secured $9M equity funding for fintech pivot.OPGN
Q4 202313 Jun 2025 - OpGen's revenue collapsed and liquidity remains critical as it pursues a sale or strategic transaction.OPGN
Q2 202413 Jun 2025 - Revenue plunged 82% as OpGen pivots to survival mode amid insolvencies and urgent funding needs.OPGN
Q1 202413 Jun 2025